News

4/27/23

The Wall Street Journal: Lisa Khan Blocks Cancer Cures

4/3/23

The Wall Street Journal: The FTC’s Unholy Antitrust Grail

12/13/22

Reuters: Illumina defends $7.1 bln Grail buy to fend off antitrust regulators

11/21/22

Press Release by Senator Tom Cotton: Cotton Expresses Concern Over European Commission Jurisdiction Claim

11/10/22

Law360: Illumina Defends Grail Deal To FTC Commissioners After Win

10/7/22

The Wall Street Journal: Cancer-Detecting Blood Tests Gain Ground as New Market Opens Up

9/11/22

GRAIL: GRAIL Announces Final Results from the PATHFINDER Multi-Cancer Early Detection Screening Study at ESMO Congress 2022

9/7/22

MLex: Illumina-Grail deal not proven by US FTC to be illegal, administrative law judge found

9/6/22

Press Release: Illumina Intends to Appeal European Commission’s Decision in GRAIL Deal

9/1/22

Press Release: Administrative Law Judge Rules in Favor of Illumina in FTC Challenge of GRAIL Deal

7/19/22

MLex: Illumina offers EU concessions over Grail deal as merger-review clock restarts

6/13/22

Barron’s: Illumina Will Be Fine Despite Recent Concerns, Says CEO

3/21/22

POLITICO’s West Wing Playbook: Could Biden’s FTC trip up his cancer moonshot?

1/28/22

New York Times DealBook: Biden Renews Pushback Against Stock Buybacks

1/26/22

MLex: Illumina Will Seek to Overcome EU Antitrust Concerns Over Grail Deal, CEO Says

1/16/22

Financial Times: Illumina Says EU Probe of $8BN Grail Deal Could Hit Biotech Investment

10/8/21

WSJ: Regulatory Hurdles Block a Cancer Miracle

8/18/21

Press Release: Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test

3/30/21

Press Release: Illumina Committed to Pursuing GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test

9/21/20

Press Release: Illumina to Acquire GRAIL to Launch New Era of Cancer Detection